

Special Issue

Multi-target Drug Treatments for Neurodegenerative Disease

Message from the Guest Editors

One promising approach considers the inhibition of amyloid formation by small-molecule inhibitors; however, the failure of multiple clinical therapeutic approaches indicates that the current strategies must be modulated and the importance of targeting pre-symptomatic signs, such as oxidative stress and inflammation, must be emphasized. Both oxidative stress and neuroinflammation precede over the symptomatology of neurodegenerative disorders, and each promotes a neurotoxic environment associated with neurodegeneration. In this scenario, polyphenols represent a promising starting point for new preventive and therapeutic approaches, since they effectively and simultaneously target epigenetic, metabolic, inflammatory, and oxidative pathways, as well as amyloid aggregation. These molecules have global availability, low cost, and low toxicity. Improved knowledge of these topics is essential in promoting the use of natural polyphenols far beyond their known antioxidant, antidiabetic, and antilipidemic effects. Increased information on this topic could be exploited to enrich, from a commercial and nutraceutical point of view, the alimentary and healthy values of natural compounds.

Guest Editors

Dr. Manuela Leri

Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, 50134 Florence, Italy

Dr. Marzia Vasarri

Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8

CiteScore 7.7

Indexed in PubMed



[mdpi.com/si/157395](https://www.mdpi.com/si/157395)

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://www.mdpi.com/journal/pharmaceuticals)

Deadline for manuscript submissions

closed (10 March 2025)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

